Browsing: Conditions

LEO Pharma, a global leader in medical dermatology delivering innovative solutions for skin disease, has entered into an agreement to acquire worldwide rights to dersimelagon from Japan-based Tanabe Pharma. Dersimelagon is an oral, once-daily small MC1R agonist being developed for erythropoietic protoporphyria (EPP) and X-linked proto-porphyria (XLP)

Researchers at Khalifa University in Abu Dhabi have developed iGenRARE, an agentic AI platform intended to support doctors in diagnosing more than 7,000 rare diseases

DALLAS, Aug. 18, 2026 — Despite rapid advances in digital health, artificial intelligence and remote patient monitoring, many promising health technologies still fail to reach patients who need them most. To help close that gap, the American Heart Association, a relentless force changing the future of health for everyone, everywhere, is now accepting applications for…

“People have estimated that out of all the people who need palliative care, how many actually get it? It’s about 5%.”

Last month, CMS threw a wrench into the remote patient monitoring arena by announcing plans to end Medicare payment for third-party RPM services. This proposal, if finalized, would mean significant changes for providers and RPM companies, as partnerships between the two are widespread. And those changes could upend patient access to healthcare

Colorado requires middle, junior high and high school coaches in public and private schools to attend training on mental health. Currently, training is required to cover concerns specific to young athletes such as anxiety disorders, depression and suicide prevention

LEO Pharma has put up $435 million to acquire a rare disease drug for two conditions that cause photosensitivity, expanding the Danish biotech’s dermatology portfolio

Investment in health tech AI is increasing, with significant funding directed towards chronic care, home health, and workforce training. In June, there were four major funding rounds totaling $335 million aimed at improving these areas. The focus includes AI scheduling and home care operations

Designation follows recent FDA clearance of the Company’s IND application for C-1101, an investigational, potentially disease-modifying non-opioid biologic

The Centers for Disease Control and Prevention still has an Alzheimer’s disease program. Congress appropriated $41 million to it this year. There’s just no one staffing it